Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
17 oct. 2024 11h00 HE
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited, a clinical-stage biotechnology company that is addressing major global infectious diseases through the...
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
02 oct. 2024 07h00 HE
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious...
Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity
22 août 2024 07h00 HE
|
Emergex Vaccines Holding Ltd
Breakthrough patent represents a significant leap in influenza pandemic preparedness, solidifying the company’s innovative approach for influenza vaccine development with viral peptides derived from a...
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
18 juin 2024 07h00 HE
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global...
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator
16 janv. 2024 07h30 HE
|
Emergex Vaccines Holding Ltd
Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point immunotherapeutic candidates with DEKA’s...
Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™
03 janv. 2024 11h16 HE
|
Emergex Vaccines Holding Ltd
Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses. Emergex is...
Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch
18 déc. 2023 07h00 HE
|
Emergex Vaccines Holding Ltd
Earlier this year, Emergex submitted a notification to the FDA regarding the transfer of ownership of Zosano Pharma’s Microneedle Array Patch (MAP) epidermal drug delivery system to Emergex itself...
Emergex Signs Contract of £1.79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
17 nov. 2023 07h00 HE
|
Emergex Vaccines Holding Ltd
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through...
Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
05 oct. 2023 07h00 HE
|
Emergex Vaccines Holding Ltd
Emergex and VIC plan to collaborate to further develop and commercialise Emergex’s proprietary T cell-based vaccine candidates as designated in Saudi Arabia and the agreed Territory (including GCC...
Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
19 juil. 2023 08h00 HE
|
Emergex Vaccines Holding Ltd
First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated Evidence for generation of virus-specific effector and memory CD8+ T cells Data reinforce findings from trial of...